19 February 2018

Manager, Company Announcements ASX Limited Level 4 20 Bridge Street SYDNEY NSW 2000

Via E-Lodgement

Dear Sir/Madam

Mayne Pharma Group Limited
Share Buy Back Employee Loan Shares

We wish to advise that 16,893,279 employee loan shares have been cancelled as previously foreshadowed at the 2017 Annual General Meeting.

As the purchase of these Shares was originally funded by a loan by the Company pursuant to the terms of the Employee Share Plan, these Shares being bought back and cancelled extinguish the loan. Accordingly, there is no cash outlay by the Company to buy back these Shares.

The total number of issued shares in the capital of the Company has been reduced to 1,524,812,822.

Yours faithfully, Mayne Pharma Group Limited

Nick Freeman

**Group CFO and Company Secretary** 



Rule 3.8A

## **Appendix 3F**

# Final share buy-back notice (except minimum holding buy-back)

Introduced 1/9/99. Origin: Appendices 7D and 7E. Amended 30/9/2001, 11/01/10

Information and documents given to ASX become ASX's property and may be made public.

Name	e of entity	ABN/ARSN	
May	ne Pharma Group Limited	76 115 832 963	
We (	(the entity) give ASX the following	information.	
Des	scription of buy-back		
1	Type of buy-back	Employee Share Plan Buy Back	
Det	ails of all shares/units bou	ght back	
2	Number of shares/units bought back	16,893,279	
3	Total consideration paid or payable for the shares/units	\$33,742,554 (no cash outlay in accordance with share loan plan rules)	
4	If buy-back is an on-market buy- back - highest and lowest price paid	highest price: not applicable date:	
		lowest price: not applicable date:	

11/01/2010 Appendix 3F Page 1

<sup>+</sup> See chapter 19 for defined terms.

### **Compliance statement**

1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here: Date: 19 Feb 2018

(Director/Company secretary)

Print name: Nick Freeman

== == == ==

Appendix 3F Page 2 11/01/2010

<sup>+</sup> See chapter 19 for defined terms.

# Australian Securities & Investments Commission

Electronic Lodgement

Document No. 7E9916890

Lodgement date/time: 19-02-2018 14:36:31 Reference Id: 108463366

**Form 484** 

Corporations Act 2001

### Change to company details

**Company details** 

Company name

**MAYNE PHARMA GROUP LIMITED** 

Australian Company Number (ACN)

115 832 963

Lodgement details

Who should ASIC contact if there is a query about this form?

Name

**Nicholas John Michael FREEMAN** 

Signature

This form must be signed by a current officeholder of the company.

I certify that the information in this form is true and complete

Name

Nicholas John Michael FREEMAN

Capacity

Secretary

Signature

Date signed

19-02-2018

### C1 Cancellation of shares

### Reason for cancellation

### Shares cancellation details

Reason for cancellation

ss.257H(3) Share buyback - Other buy-back type. A form 280 or 281 must be lodged at least 14 days, and no more than 1 year before the share buy-back can take place

The cancelled shares are listed below:

		Amount paid (cash or otherwise)	
ORD	16893279	2.00	

Earliest Date of cancellation

19-02-2018

### C3 Change to share structure

The updated details for this changed share class are shown in the table below.

Share class code	Full title if not standard	_		Total amount unpaid on these shares
ORD	ORDINARY SHARES	1524812822	1131907169.80	0.00

Earliest date of

19-02-2018

change